-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 14, SciNeuro Pharmaceuticals announced that it had signed an exclusive license agreement with Eli Lilly and Company for development and commercialization in Greater China (including Mainland China, Hong Kong, Macau and Taiwan) This is a targeted therapy called "α-synuclein" (α-synuclein).
Saishen Medicine focuses on the field of central nervous system diseases.
In December 2020, it announced that it officially set sail and completed a US$100 million Series A financing.
The founder and CEO is Dr.
Limin.
In this cooperation with Eli Lilly, Celestine Pharma has obtained the exclusive license to develop Eli Lilly’s α-synuclein-targeted antibody in the Greater China region.
How does alpha-synuclein affect neurological diseases? According to reports in the literature, in the brains of many patients with neurodegenerative diseases, some proteins will aggregate to form chain-like amyloid fibril (amyloid fibril).
Source: 123RF
“There are currently about 3 million elderly people in Greater China affected by Parkinson’s disease, causing a huge disease burden.
Dr.